MHC class I molecules are central to the detection of intracellular abnormalities by CD8+ T lymphocytes. They bind peptide fragments derived from proteasomal degradation of cellular proteins and ...
Intestinal epithelial cells (IECs) are more than a passive barrier; they serve as non-professional antigen-presenting cells by expressing major histocompatibility complex class II (MHC class II) ...
In a recent article posted to the bioRxiv* preprint server, researchers demonstrated the sarbecovirus open reading frame 7a (ORF7a)-induced hindrance of the antigen presentation by the major ...
Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer. This is an ASCO Meeting ...
CHARLESTON, S.C., April 13, 2026--(BUSINESS WIRE)--Leukogene Therapeutics, Inc., an early‑stage oncology company developing MHC class II-engager immunotherapies for immunologically cold cancers, today ...
Clinical utilization of precision oncology decision support for genomically-informed cancer therapy. PD-1, PD-L1, and B7-H3 expression in Human Immunodeficiency Virus (HIV) infected patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results